関連する実験動画
Updated: Jun 26, 2025

10:09
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
8.3K
非正規PI3Kγシグナリングによる標的型白血病の依存性
Qingyu Luo1, Evangeline G Raulston1, Miguel A Prado2,3
1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Nature
|May 8, 2024
まとめ
この研究は,急性白血病の新たな標的であるフォスフォノシチド-3-キナーゼ-ガンマ (PI3Kγ) とその経路を明らかにした. PI3Kγを抑制することは,特に他の治療法と併用すると,白血病の治療に有望である.
科学分野:
- 腫瘍学
- 免疫学
- 分子生物学
背景:
- 固体がんにおける抗腫瘍免疫に影響することが知られている.
- 特に白血病におけるPI3Kγの特定の役割は,ほとんど不明である.
研究 の 目的:
- 急性白血病におけるPI3Kγの細胞内機能を調査する.
- 白血病の治療のためのPI3Kγシグナル伝達経路内の潜在的な治療標的を特定する.
主な方法:
- 様々な急性白血病に対して全ゲノムCRISPR干渉スクリーニングが採用されました.
- PI3Kγ経路の活性化と下流効果を理解するために,機能的分析が行われました.
- この研究では 遺伝子スクリーニングと生化学的および細胞的検査を統合した.
主要な成果:
- 急性白血病のサブセットは,PI3Kγ複合体への依存を示し,PIK3R5の活性化と先天的な炎症シグナル伝達に関連しています.
- PI3Kγは,この依存性の主要な媒介体であるp21 (RAC1) 活性化キナーゼ1 (PAK1) を直接リン酸化する.
- PI3Kγの抑制は,PAK1の脱リン酸化に影響することで,ミトコンドリアの酸化リン酸化を阻害する.
- PI3Kγ阻害剤エガネリシブは,PIK3R5が活性化された白血病の治療に有効であることが示された.
- 臨床前モデルでは,PIK3R5の発現が低い場合でも,エガネリシブとサイトラビンの併用療法により生存率が改善されました.
結論:
- PI3Kγ-PAK1シグナリングは,急性白血病の標的依存性を表しています.
- 特にエガネリシブによるPI3Kγの標的化は,白血病に対する潜在的な治療戦略です.
- PI3Kγ阻害剤を併用した併用療法では有効性が向上し,臨床評価が必要である.
関連する概念動画
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K

